Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00648882 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00648882 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT00648882, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 300 mcg tablets to Abbott's Synthroid® 300 mcg tablets following a single, oral 600 mcg dose (2 × 300 mcg) administered under fasting conditions.
Interventions
- DRUG LEVOTHYROXINE SODIUM TABLETS,
- DRUG SYNTHROID® 300 mcg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00648882
The ClinicalTrials.gov registry entry for NCT00648882 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LEVOTHYROXINE SODIUM TABLETS, is the first listed.
NCT00648882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00648882 about?
NCT00648882 is a clinical study titled "Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg". The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 300 mcg tablets to Abbott's Synthroid® 300 mcg tablets following a single, oral 600 mcg dose (2 × 300 mcg) administered under fasting conditions.
What is the current status of trial NCT00648882?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2007-03. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00648882?
The interventions under investigation include: LEVOTHYROXINE SODIUM TABLETS, (DRUG), SYNTHROID® 300 mcg Tablets (DRUG).
Who is sponsoring clinical trial NCT00648882?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.